Eterna Therapeutics
ERNA
9 hedge funds and large institutions have $2.99M invested in Eterna Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 6 → 9 (+3)
1% less capital invested
Capital invested by funds: $3.01M → $2.99M (-$21K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
+$996K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$52.4K |
| 3 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
+$52.4K |
| 4 |
Renaissance Technologies
New York
|
+$52.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$52.4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NSIM
1
North Star Investment Management
Chicago,
Illinois
| $1.22M | +$52.4K | +1 | +5% |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $1.07M | +$996K | +19 | New |
|
|
3
Renaissance Technologies
New York
| $206K | +$52.4K | +1 | +33% |
|
4
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $114K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $82K | +$52.4K | +1 | New |
|
6
Geode Capital Management
Boston,
Massachusetts
| $80K | – | – | – |
|
|
CA
7
Callahan Advisors
Houston,
Texas
| $71K | – | – | – |
|
8
Vanguard Group
Malvern,
Pennsylvania
| $62K | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| $59K | +$52.4K | +1 | New |
|
10
UBS Group
Zurich,
Switzerland
| $12K | – | – | – |
|
11
BlackRock
New York
| $11K | – | – | – |
|
|
LTFS
12
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
ERNA Hedge Fund Activity: Q2 2019 in Review
9 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2019, worth a combined $2.99M — down 0.7% from $3.01M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ERNA positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Bard Associates, opening a new position worth an estimated $996K.
- 9 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2019, up from 6 in Q1 2019.
- Funds reported $2.99M of Eterna Therapeutics stock for Q2 2019, down 0.7% quarter-over-quarter.
- 3 funds opened new Eterna Therapeutics positions in Q2 2019 and 0 closed out, a net change of +3 holders.
- The largest Eterna Therapeutics buyer in Q2 2019 was Bard Associates, an estimated $996K added.
Based on aggregated 13F filings for Q2 2019.